Health and Healthcare
The Generic Boniva Opportunity (RHHBY, MYL)
Published:
Last Updated:
The Food and Drug Administration approval of the first generic versions of osteoporosis drug Boniva won’t be the end of Roche Holding AG (OTC: RHHBY) for its marketing of Boniva in the United States. It will however help out smaller generic players like Apotex, Orchid, and Mylan Inc. (NASDAQ: MYL).
What makes Boniva unique in the osteoporosis market other than that Sally Fields was the ad woman is that it is a once per month tablet marketed to prevent osteoporosis in women after menopause. The osteoporosis drug aims to help increase bone mass to reduce the risks associated with weak bones and spinal fractures in women.
Apotex previously agreed not to sell the drug until the patent rulings were out, so the FDA allowance for generics will allow generics to begin selling. There is an interesting set of figures. At least 5 million patients are on one of the drugs under the class called “bisphosphonate therapy” which Boniva is one of several in that class. Drugs.com noted that the total size of the osteoporosis market is $18 billion in the United States.
Mylan shares are down slightly on the day. What portion of this generic market it can capture is still an unknown.
JON C. OGG
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.